Background. Over the past ten years, the incidence rate of papillary thyroid carcinoma (PTC)
worldwide has been increasing rapidly year by year, with the incidence rate increasing 6 …

Over the past 3 decades, advances in the molecular genetics of thyroid cancer (TC) have
been translated into diagnostic tests, prognostic markers, and therapeutic agents. The main …

Background The objective of this study is to perform a meta-analysis to evaluate the
associations between the BRAF V600E mutation status and aggressive clinicopathological …

Objective To investigate the mutant status of BRAF gene and analyze its relationship to
epidemiological risk factors and clinical outcomes among patients with papillary thyroid …

BACKGROUND Bilaterality is common in papillary thyroid cancer (PTC), but its clinical and
prognostic implications are still controversial, and it remains unclear whether its behavior is …

The prognostic role of molecular markers in papillary thyroid carcinoma (PTC) is a matter of
ongoing debate. The aim of our study is to investigate the impact of RAS, BRAF, TERT …

Thyroid cancer derived from follicular cells (TCDFC) comprises well-differentiated (papillary
and follicular) carcinoma, poorly differentiated carcinoma, and anaplastic carcinoma …

Background Presence of lymph node metastases increases the risk of recurrence, but
prophylactic central neck node dissection for patients with micropapillary thyroid cancer …

Context: Papillary thyroid carcinoma (PTC) carrying the BRAF mutation has been reported to
be associated with high recurrence and potentially increased mortality. PTC carrying the …

Concordance between mutations in the primary papillary thyroid carcinoma (PTC) and the
paired x lymph node metastasis may elucidate the potential role of molecular targeted …